MedTrace Logo

Rosuvastatin ORBITAL Germany

NCT00379249 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 8000

Last updated 2009-03-26

No results posted yet for this study

Summary

The primary objective of the study is to compare the effect of rosuvastatin therapy plus compliance initiatives and rosuvastatin therapy alone for 12 months (52 weeks) on long-term cumulative direct and indirect disease-related costs during the 36 month.

Conditions

Interventions

DRUG

Rosuvastatin

Sponsors & Collaborators

Principal Investigators

  • Wolfgang Meyer - Sabellek, MD · AstraZeneca Germany

  • Stefan Stefan Willich, MD · Charité Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28
Completion
2004-02-29

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00379249 on ClinicalTrials.gov